Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MSC versus placebo plus MMF for steroid-refractory acute graft-versus-host disease
NL-OMON27391Phase 3Not yet recruiting
- Sponsor
- HOVON
- Start
- Nov 2013
- Modality
- Mesenchymal Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Provacel in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by HOVON. Planned start Nov 2013; status: not yet recruiting.
02
Drugs
Provacel
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NL-OMON27391.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON27391.